Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market from 2024 to 2025?
In recent times, the market size of the vesicular monoamine transporter 2 (VMAT2) inhibitor has experienced fast-paced growth. Projections indicate a growth from $1.13 billion in 2024 to $1.25 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 10.6%. Factors driving this growth in the historic period include an uptick in cases of movement disorders, increased demand for effective treatment methods, enhanced awareness of tardive dyskinesia, a rise in the elderly population, and an expanded preference for oral formulations.
What Is the Projected Market Size of the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
In the coming years, the market for vesicular monoamine transporter 2 (VMAT2) inhibitors is set to witness substantial growth, with predictions suggesting it will surge to $1.85 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. The forecasted growth could be credited to factors such as the increasing occurrence of neurodegenerative diseases, the growing acceptance of targeted therapies, a heightened emphasis on personalized medicine, elevated investment in research and development, and increased consciousness about psychiatric and movement disorders. The anticipated trends during the forecast period include progression in neurological research, evolution in drug formulations, a transition towards personalized and precision medicine, advancement of next-generation VMAT2 inhibitors, and the incorporation of digital health technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp
Who are the Major Competitors in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook?
Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH
What Is Fueling Growth in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
The growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market is anticipated to be driven by the rising occurrence of Parkinson’s disease. This progressive neurological disorder impacts movement due to the decline of dopamine-producing cells in the brain. Factors such as an ageing population, improved diagnosis, environmental toxins, genetic roles, and increased awareness contribute to the growing occurrence of Parkinson’s disease. VMAT2 inhibitors contribute to the management of Parkinson’s symptoms by regulating dopamine release and minimizing tremors and dyskinesia. For instance, in December 2022, the Parkinson’s Foundation, a US-based nonprofit organization, stated that almost 90,000 people were diagnosed with Parkinson’s disease in the U.S., reflecting a 50% rise from the earlier annual diagnosis estimate of 60,000. Therefore, the escalating occurrence of Parkinson’s disease is fueling the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21317&type=smp
Which Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Segments Are Growing the Fastest?
The vesicular monoamine transporter 2 (VMAT2) inhibitor market covered in this report is segmented –
1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs
2) By Route Of Administration: Oral, Other Administrations
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment
2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders
3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders
4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions
Which Industry Trends Are Shaping the Future of the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
Leading firms in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are concentrating on the creation of innovative versions, such as capsules, to increase patient adherence, enhance medicine longevity, and maximize therapeutic effectiveness. Capsules, which are robust dosage forms enclosed in a gelatin or HPMC shell, aid VMAT2 inhibitors by boosting the stability of the medication, promoting accurate dosage, and improving patient adherence. For example, Neurocrine Biosciences Inc., a biopharmaceutical firm based in the United States, introduced Ingrezza Sprinkle capsules in July 2024. This new VMAT2 inhibitor formulation, Ingrezza, is engineered to simplify administration for adults suffering from tardive dyskinesia and Huntington’s disease-related chorea who struggle with dysphagia or swallowing difficulties. Ingrezza Sprinkle provides the same effective dosage alternatives as Ingrezza and can be taken by sprinkling the capsule content on soft food or directly swallowing the entire capsule.
Access The Full Report Here:
Which Countries Are Leading the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21317
This Report Delivers Insight On:
1. How big is the vesicular monoamine transporter 2 (vmat2) inhibitor market, and how is it changing globally?
2. Who are the major companies in the vesicular monoamine transporter 2 (vmat2) inhibitor market, and how are they performing?
3. What are the key opportunities and risks in the vesicular monoamine transporter 2 (vmat2) inhibitor market right now?
4. Which products or customer segments are growing the most in the vesicular monoamine transporter 2 (vmat2) inhibitor market?
5. What factors are helping or slowing down the growth of the vesicular monoamine transporter 2 (vmat2) inhibitor market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
